Form 8-K - Current report:
SEC Accession No. 0001649094-24-000096
Filing Date
2024-11-05
Accepted
2024-11-05 16:03:10
Documents
15
Period of Report
2024-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcvx-20241105.htm   iXBRL 8-K 27171
2 EX-99.1 pcvx-20241105xexx991.htm EX-99.1 86123
6 img251305552_0a.jpg GRAPHIC 9918
  Complete submission text file 0001649094-24-000096.txt   266609

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pcvx-20241105.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pcvx-20241105_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pcvx-20241105_pre.xml EX-101.PRE 13046
17 EXTRACTED XBRL INSTANCE DOCUMENT pcvx-20241105_htm.xml XML 2811
Mailing Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39323 | Film No.: 241427371
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)